文献速递消化系统肿瘤

TRIBE2研究:一线FOLFOXIRI联合贝伐珠单抗及进展后原方案再引入对比双药序贯联合贝伐珠单抗治疗转移性结直肠癌

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2020-03-09

TRIBE2是一项多中心、开放标签、3期随机对照试验,纳入679例不可切除、既往未治疗的转移性结直肠癌患者,比较一线FOLFOXIRI联合贝伐珠单抗、进展后再引入原方案与mFOLFOX6联合贝伐珠单抗序贯FOLFIRI联合贝伐珠单抗两种策略。

要点

  • 一线FOLFOXIRI联合贝伐珠单抗及进展后再引入原方案,较双药序贯联合贝伐珠单抗显著改善无进展生存期2。
  • 实验组一线治疗期间3-4级腹泻、中性粒细胞减少及严重不良事件发生率高于对照组。
  • 实验组治疗相关死亡8例,对照组4例;进展后除神经毒性外两组3-4级不良事件无实质差异。

核心结论

  • 对于符合研究入选标准的转移性结直肠癌患者,一线FOLFOXIRI联合贝伐珠单抗、进展后再引入原方案的策略似乎优于双药序贯联合贝伐珠单抗。

研究设计与样本

  • TRIBE2为多中心、开放标签、3期随机对照试验,自意大利58个肿瘤中心招募18-75岁、ECOG体力状态2分、不可切除且既往未治疗的转移性结直肠癌患者。
  • 共679例患者随机分配并接受治疗,对照组340例,实验组339例;按中心、ECOG体力状态、原发肿瘤部位和既往辅助化疗分层。
  • 主要终点为无进展生存期2,定义为从随机化至首次疾病进展后任一治疗期间疾病进展或死亡的时间,按意向治疗分析。

主要发现

  • 一线治疗期间,实验组与对照组最常见的全因3-4级事件分别为腹泻57例(17%)对18例(5%)、中性粒细胞减少168例(50%)对71例(21%)、动脉高血压25例(7%)对35例(10%)。
  • 实验组严重不良事件84例(25%),对照组56例(17%);实验组治疗相关死亡8例,对照组4例。
  • 首次疾病进展后,除神经毒性仅见于实验组(132例中6例,5%)外,两组3-4级不良事件发生率无实质差异;实验组严重不良事件20例(15%),对照组25例(12%)。
  • 首次疾病进展后,实验组治疗相关死亡3例,对照组4例。

临床怎么用

  • 在符合TRIBE2入选标准的转移性结直肠癌患者中,可考虑一线FOLFOXIRI联合贝伐珠单抗、进展后再引入原方案的策略。
  • 采用该策略需关注一线治疗期间腹泻、中性粒细胞减少等3-4级不良事件及严重不良事件的发生风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. However, the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear, and neither was the feasibility or efficacy of therapies after disease progression. We aimed to compare a preplanned strategy of upfront FOLFOXIRI followed by the reintroduction of the same regimen after disease progression versus a sequence of mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) and FOLFIRI doublets, in combination with bevacizumab. METHODS: TRIBE2 was an open-label, phase 3, randomised study of patients aged 18-75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2, with unresectable, previously untreated metastatic colorectal cancer, recruited from 58 Italian oncology units. Patients were stratified according to centre, ECOG performance status, primary tumour location, and previous adjuvant chemotherapy. A randomisation system incorporating a minimisation algorithm was used to randomly assign patients (1:1) via a masked web-based allocation procedure to two different treatment strategies. In the control group, patients received first-line mFOLFOX6 (85 mg/m2 of intravenous oxaliplatin concurrently with 200 mg/m2 of leucovorin over 120 min; 400 mg/m2 intravenous bolus of fluorouracil; 2400 mg/m2 continuous infusion of fluorouracil for 48 h) plus bevacizumab (5 mg/kg intravenously over 30 min) followed by FOLFIRI (180 mg/m2 of intravenous irinotecan over 120 min concurrently with 200 mg/m2 of leucovorin; 400 mg/m2 intravenous bolus of fluorouracil; 2400 mg/m2 continuous infusion of fluorouracil for 48 h) plus bevacizumab after disease progression. In the experimental group, patients received FOLFOXIRI (165 mg/m2 of intravenous irinotecan over 60 min; 85 mg/m2 intravenous oxaliplatin concurrently with 200 mg/m2 of leucovorin over 120 min; 3200 mg/m2 continuous infusion of fluorouracil for 48 h) plus bevacizumab followed by the reintroduction of the same regimen after disease progression. Combination treatments were repeated every 14 days for up to eight cycles followed by fluorouracil and leucovorin (at the same dose administered at the last induction cycle) plus bevacizumab maintenance until disease progression, unacceptable adverse events, or consent withdrawal. Patients and investigators were not masked. The primary endpoint was progression-free survival 2, defined as the time from randomisation to disease progression on any treatment given after first disease progression, or death, analysed by intention to treat. Safety was assessed in patients who received at least one dose of their assigned treatment. Study recruitment is complete and follow-up is ongoing. This trial is registered with Clinicaltrials.gov, NCT02339116. FINDINGS: Between Feb 26, 2015, and May 15, 2017, 679 patients were randomly assigned and received treatment (340 in the control group and 339 in the experimental group). At data cut-off (July 30, 2019) median follow-up was 35·9 months (IQR 30·1-41·4). Median progression-free survival 2 was 19·2 months (95% CI 17·3-21·4) in the experimental group and 16·4 months (15·1-17·5) in the control group (hazard ratio [HR] 0·74, 95% CI 0·63-0·88; p=0·0005). During the first-line treatment, the most frequent of all-cause grade 3-4 events were diarrhoea (57 [17%] vs 18 [5%]), neutropenia (168 [50%] vs 71 [21%]), and arterial hypertension (25 [7%] vs 35 [10%]) in the experimental group compared with the control group. Serious adverse events occurred in 84 (25%) patients in the experimental group and in 56 (17%) patients in the control group. Eight treatment-related deaths were reported in the experimental group (two intestinal occlusions, two intestinal perforations, two sepsis, one myocardial infarction, and one bleeding) and four in the control group (two occlusions, one perforation, and one pulmonary embolism). After first disease progression, no substantial differences in the incidence of grade 3 or 4 adverse events were reported between the control and experimental groups, with the exception of neurotoxicity, which was only reported in the experimental group (six [5%] of 132 patients). Serious adverse events after disease progression occurred in 20 (15%) patients in the experimental group and 25 (12%) in the control group. Three treatment-related deaths after first disease progression were reported in the experimental group (two intestinal occlusions and one sepsis) and four in the control group (one intestinal occlusion, one intestinal perforation, one cerebrovascular event, and one sepsis). INTERPRETATION: Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria. FUNDING: The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020. PMID: 32164906. doi:10.1016/S1470-2045(19)30862-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。